NCT06483009尚未招募2 期
Efficacy and Safety of Combination Therapy of Sintilimab and Chemotherapy With Cryoablation in the First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 20
- 主要终点
- Progression-free survival (PFS)
研究概览
简要总结
This study aims to investigate the efficacy and safety of immuno-chemotherapy in combination of cryoablation as the first-line treatment of advanced NSCLC
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥18 years and ≤75 years.
- •Histologically or cytologically confirmed locally advanced (IIIB-IIIC), metastatic, or recurrent (stage IV) non-squamous NSCLC (as per the International Association for the Study of Lung Cancer and the American Joint Committee on Cancer 9th edition TNM lung cancer staging), with T staging ranging from T1 to T2b, not amenable to surgical treatment and definitive concurrent chemoradiotherapy, and have not previously received systemic treatment.
- •Maximum diameter of the primary lesion <5cm and located in a relatively isolated area, not adjacent to major blood vessels or major structures.
- •Absence of EGFR gene sensitizing mutations and ALK gene fusion mutations confirmed by histopathology specimens.
- •At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1), with lesions located within previously irradiated fields considered measurable if confirmed to have progressed.
- •No prior systemic anti-tumor therapy for advanced/metastatic disease. Patients who have previously received platinum-based adjuvant/neoadjuvant chemotherapy, or definitive chemoradiotherapy for advanced disease, may be included if disease progression or recurrence has occurred at least 6 months after the end of the last chemotherapy regimen.
- •Patients with asymptomatic or stable symptomatic brain metastases may be included if they meet specific conditions: a) Measurable lesions outside the central nervous system. b) Absence of central nervous system symptoms or stable symptoms for at least 2 weeks. c) No need for corticosteroid treatment, or discontinuation of corticosteroid treatment within 7 days before the first dose of study drug, or stable corticosteroid dose reduced to ≤10mg/day prednisone (or equivalent) within 7 days before the first dose of study drug.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0-
- •Expected survival >3 months.
- •Adequate organ function, with the following laboratory criteria:
- •Absolute neutrophil count (ANC) ≥1.5x10^9/L without granulocyte colony-stimulating factor use in the past 14 days.
- •Platelet count ≥100×10^9/L without blood transfusion in the past 14 days.
排除标准
- •Pathologically confirmed small cell lung cancer (SCLC), including lung cancer mixed with SCLC and NSCLC.
- •Diagnosed with malignancies other than NSCLC within 5 years before the first dose of study drug (excluding cured basal cell carcinoma, squamous cell carcinoma of the skin, and/or in situ carcinoma).
- •Previously received therapy including anti-PD-1, anti-PD-L1, or anti-PD-L2 drugs, or drugs targeting another T cell receptor for stimulation or co-inhibition (e.g., CTLA-4, OX-40, CD137).
- •Active autoimmune diseases requiring systemic treatment within 2 years before the first dose of study drug. Alternative therapy (e.g., thyroid hormone, insulin, or physiological corticosteroids for adrenal or pituitary insufficiency) is not considered systemic treatment.
- •Pregnant or lactating women
- •Presence of any severe or uncontrollable systemic diseases
- •Medical history, disease evidence, treatment, or laboratory test abnormalities that may interfere with the study results or hinder subjects' participation in the study throughout its duration, or other conditions deemed unsuitable for enrollment by the investigator due to potential risks.
- •Diffuse lesions in both lungs where ablation therapy cannot improve the condition.
- •Extensive pleural metastases with large amounts of pleural effusion.
- •Difficulty in needle puncture due to proximity of the tumor to major mediastinal vessels or difficulty in selecting a puncture path due to contrast agent allergy or patient non-compliance.
- •Severe impairment of lung function, with maximum ventilation <40%.
结局指标
主要结局
Progression-free survival (PFS)
时间窗: up to 3 years
Assessed by the investigators using the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 and iRECIST. In case of any discrepancies, the investigators will consult a third party.
次要结局
- Disease control rate (DCR)(up to 3 year)
- Objective response rate (ORR)(up to 3 years)
- Duration of response (DOR)(up to 3 years)
- Safety profile(up to 3 years)
研究者
Hua Zhong
Chief of Respiratory Department
Shanghai Chest Hospital
相似试验
Unknown
3 期
Efficacy of Cryotherapy Combined With Intralesional Tuberculin PPD Versus Intralesional Tuberculin PPD in Treatment of Multiple Common WartsCommon WartNCT04288817Assiut University40
终止
1 期
Epicutaneous Cryoimmunotherapy Combined With Pembrolizumab for Cutaneous Metastatic Breast CancerMetastatic Breast CancerNCT03982004Washington University School of Medicine1
已完成
3 期
Efficacy of freeze in treatment of cervical erosioSymptomatic chronic cervicitis.Endocervicitis with or without erosion or ectropionIRCT2014101719559N1Vice chancellor for research, Sabzevar University of Medical Sciences130
进行中（未招募）
2 期
Phase II Study of Combined Chemotherapy With Arsenic Trioxide in Stage 4/M NeuroblastomaNeuroblastomaNCT03503864Yang Li80
尚未招募
1 期
Combination Chemotherapy With Pazopanib in Children and Adolescents With Relapsed/Refractory Solid TumorsRelapsed Pediatric Solid TumorRefractory Pediatric Solid TumorNCT03628131Samsung Medical Center46